We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00121329
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : July 21, 2005
Sponsor:
Information provided by:

July 13, 2005
July 21, 2005
July 21, 2005
Not Provided
Not Provided
VAS scores during cervical dilation and uterine aspiration
Same as current
No Changes Posted
Patient satisfaction, symptoms, lidocaine levels
Same as current
Not Provided
Not Provided
 
4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions
4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions
Recent studies have investigated the use of local anesthetics (i.e. lidocaine, mepivacaine) to lessen the pain experienced with minor gynecologic procedures such as endometrial biopsy and office hysteroscopy. Local anesthetic injected into the uterine cavity has been demonstrated effective in some studies at decreasing patient pain associated with these intrauterine procedures at an anesthetic concentration of at least 2%. Based on this evidence, we hypothesized that an intrauterine lidocaine infusion may reduce patient pain during first trimester abortions.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Pain
Drug: Intrauterine lidocaine infusion 4%
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
December 2004
Not Provided

Inclusion Criteria:

  • Age > 18 years old
  • Good general health
  • English speaking
  • Confirmation of gestational age by ultrasound
  • Body weight > 100 lbs.
  • Pregnancy < 11 weeks
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00121329
OHSU IRB 6876
Not Provided
Not Provided
Not Provided
Not Provided
Oregon Health and Science University
Not Provided
Principal Investigator: Alison B Edelman, MD, MPH Oregon Health and Science University
Oregon Health and Science University
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP